Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

self-limited neonatal seizures (SeLNE) - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

self-limited neonatal seizures

MONDO:0800479

Also known as:SeLNE

Overview

A neonatal/infantile epilepsy syndrome where seizures start in the neonate between day 4 and 7 of life and are often unilateral clonic events that recur and may alternate sides from seizure to seizure. Seizures can be repetitive over hours to days. Seizures remit by 4-6 months of age. A proportion of those affected may have seizures in later life. The child is expected to have normal developmental progress. This is distinguished from familial neonatal epilepsy on the basis of family history. These entities may have similar genetic etiologies, with de novo mutations responsible for the lack of family history in self-limited neonatal seizures.

Treatments1 FDA approved

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for self-limited neonatal seizures, including PHENOBARBITAL SODIUM (SEZABY, approved 2022). An additional 2 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for self-limited neonatal seizures.

31 publications have been identified in PubMed for self-limited neonatal seizures. Research spans Case Report / Case Series (33%), Epidemiology / Natural History (33%), and Basic Science / Preclinical (17%).

Research Type	Count	% of Total
Patient case studies	10	33%

Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 4:36 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of SEZABY for managing self-limited neonatal seizures?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
topiramate	topiramate	PrevEP Inc.	2024	—	Designated
levetiracetam	levetiracetam	University of California	2010	—	Designated

Kisho

self-limited neonatal seizures

Overview

Treatment

Approved Therapies

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

self-limited neonatal seizures

Overview

Treatment

Approved Therapies

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications